{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.48","upperLimit":"8.78","value":"7.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"}],"units":"Participants"}],"description":"Duration of response, calculated for responders only, was defined as time from the initial documented response (SCR, CR, VGPR or PR) to the first confirmed disease progression, or death if no disease progression was recorded. Participants without a documented progression were censored at the time of their last tumor assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle until the documentation of confirmed progressive disease (PD), intolerable toxicity, death, withdrawal of participation in the study/consent, lost to follow-up, or as long as they benefited from therapy according to the opinion of the responsible study investigator.","id":"OG000","title":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)"}],"paramType":"MEDIAN","populationDescription":"Includes participants with a response (sCR, VGPR or PR).","reportingStatus":"POSTED","timeFrame":"From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months","title":"Kaplan Meier Estimate of Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}